Long acting GLP-1 receptor agonist (injectable)
Bofanglutide 18 mg injection every 2 weeks
BOFANG_SC_18MG_Q2W
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -10.05 (-17.07 to -1.32) | 0.64 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -10.65 (-16.26 to -2.37) | 0.71 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 2.07 (-5.46 to 9.04) | 0.67 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 3.17 (0.48 to 22.55) | 0.26 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.44 (2.37 to 13.12) | 0.30 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.23 (0.90 to 5.42) | 0.72 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.05 (0.87 to 4.74) | 0.47 |